<DOC>
	<DOCNO>NCT01146028</DOCNO>
	<brief_summary>The purpose bioequivalence study compare test Tizanidine Hydrochloride 4mg tablet Dr.Reddys Laboratories Limited reference zanaflex® 4mg tablet Elan healthy adult subject fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Tizanidine HCl Tablets 4 mg Dr.Reddys Under Fasting Conditions</brief_title>
	<detailed_description>Randomized , 2-way crossover , bioequivalence study Tizanidine Hydrochloride 4mg tablet zanaflex® 4mg tablet administer As 1 x 4mg tablet healthy adult subject fasting condition</detailed_description>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may do use different medium ( e.g . radio , newspaper , Anapharm Web site ) . Subjects must meet follow criterion order include study : Subjects females and/or male , smoker nonsmoker , 18 year age old . Female subject postmenopausal surgically sterilize . Postmenopausal status define absence menses past 12 month . Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Subjects follow applies exclude study : Clinically significant abnormality find medical screening . Clinically significant surgery within 4 week prior administration study medication . Clinically significant illness within 4 week administration study medication . History neuromuscular disease . Abnormal laboratory test judge clinically significant . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 100 140 mmHg , diastolic blood pressure low 70 90 ; heart rate le 60 bpm ) screening . Subjects BMI ≥ 30.0 . History allergic reaction tizanidine hydrochloride . Any food allergy , intolerance , restriction , special diet opinion medical sub investigator , contraindicate subject 's participation study . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HN screen . Positive urine pregnancy test screening . Donation plasma ( 500 mL ) within 7 day donation significant loss whole blood ( 500 mL ) within 56 day prior administration study medication . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( l Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana , pot ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Subjects take prescription medication within 14 day prior administration study medication overthecounter product within 7 day prior administration study medication , except topical product without systemic absorption . Smoking 25 cigarette per day . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) , use investigational drug participation investigational study within 30 day prior administration study medication . Any reason , opinion medical sub investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>